Literature DB >> 31346985

Clinical Application of Bioprosthesis in China: Current Status and Future.

Yin Wang1, Wei-Wei Jiang2, Nian-Guo Dong3.   

Abstract

China is one of the countries which have a high incidence of heart valvular disease, but the use of biological valve is limited in China before because the majority of patients are young patients suffering from rheumatic heart disease. The biological valve has a good application prospect in China. On the one hand, the new generation of biological valves have been significantly improved in the aspects of anti-calcification treatment, anti-metabolism, material quality control, valve frame mechanics design, and leaflet sewing technology, and the application effect is improved; on the other hand, surgeons should adapt to the new concept changes, and correctly understand and rationally apply biological valves, master valve repair, atrial fibrillation ablation and other techniques, combined with interventional, minimally invasive techniques, etc., according to the specific conditions of the disease and choose the surgery type to ensure the patients' long-term life quality.

Entities:  

Keywords:  China; biological valve; clinical application; valve surgery

Mesh:

Year:  2019        PMID: 31346985     DOI: 10.1007/s11596-019-2068-5

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  15 in total

1.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2009-12-17       Impact factor: 29.690

2.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

3.  Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old.

Authors:  Tsuyoshi Kaneko; Sary Aranki; Quratulain Javed; Siobhan McGurk; Prem Shekar; Michael Davidson; Lawrence Cohn
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-27       Impact factor: 5.209

4.  National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements.

Authors:  Abby J Isaacs; Jeffrey Shuhaiber; Arash Salemi; O Wayne Isom; Art Sedrakyan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-11       Impact factor: 5.209

5.  Evolution of allograft aortic valve replacement over 13 years: results of 275 procedures.

Authors:  J J M Takkenberg; L A van Herwerden; M J C Eijkemans; J A Bekkers; A J J C Bogers
Journal:  Eur J Cardiothorac Surg       Date:  2002-04       Impact factor: 4.191

Review 6.  Choice of prosthetic heart valve in adults an update.

Authors:  Shahbudin H Rahimtoola
Journal:  J Am Coll Cardiol       Date:  2010-06-01       Impact factor: 24.094

7.  Tissue heart valve mineralization: Review of calcification mechanisms and strategies for prevention.

Authors:  E Jorge-Herrero; J M Garcia Paez; J L Del Castillo-Olivares Ramos
Journal:  J Appl Biomater Biomech       Date:  2005 May-Aug

8.  Mid- to long-term outcome comparison of the Medtronic Hancock II and bi-leaflet mechanical aortic valve replacement in patients younger than 60 years of age: a propensity-matched analysis.

Authors:  Yin Wang; Si Chen; Jiawei Shi; Geng Li; Nianguo Dong
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-12-15

Review 9.  A Systematic Review of Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation for Rheumatic Mitral Regurgitation.

Authors:  Christos G Mihos; Andres M Pineda; Romain Capoulade; Orlando Santana
Journal:  Ann Thorac Surg       Date:  2016-06-17       Impact factor: 4.330

10.  Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population.

Authors:  Yin Wang; Si Chen; Xing-Jian Hu; Jia-Wei Shi; Nian-Guo Dong
Journal:  Chin Med J (Engl)       Date:  2015-12-20       Impact factor: 2.628

View more
  2 in total

1.  Improved Cytocompatibility and Reduced Calcification of Glutaraldehyde-Crosslinked Bovine Pericardium by Modification With Glutathione.

Authors:  Zhenlin Jiang; Zhongshi Wu; Dengpu Deng; Jiemin Li; Xiaoke Qi; Mingzhe Song; Yuhong Liu; Qiying Wu; Xinlong Xie; Zeguo Chen; Zhenjie Tang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-19

2.  Bioprosthetic vs mechanical mitral valve replacement for infective endocarditis in patients aged 50 to 69 years.

Authors:  Xingjian Hu; Weiwei Jiang; Minghui Xie; Ruikang Guo; Wai Yen Yim; Nianguo Dong; Yin Wang
Journal:  Clin Cardiol       Date:  2020-06-04       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.